US Patent:
20200078376, Mar 12, 2020
Inventors:
- Oakland CA, US
Anil Bhushan - San Francisco CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 31/635
A61K 31/496
A61K 31/4025
A61K 31/5377
A61K 31/506
A61K 31/4412
A61K 31/427
A61K 31/4725
A61K 31/353
A61K 31/4545
A61K 31/12
A61K 31/45
A61K 31/5517
A61K 31/551
A61K 31/5415
A61K 31/55
A61K 31/517
A61K 31/437
A61K 31/519
A61K 31/541
A61K 31/145
A61K 31/41
A61P 3/10
Abstract:
The inventor of the present disclosure has advantageously elucidated the role of senescent processes in the development of Type 1 diabetes. Genotoxic stress responses, senescence, and acquisition of a SASP condition in beta cells are drivers that progress at-risk individuals to overt Type 1 diabetes. The administration of senolytic agents to at risk individuals selectively removes senescent cells and relieves beta cells from the factors which drive the development of overt Type 1 diabetes. Accordingly, Type 1 diabetes can be prevented in at-risk individuals by the administration of senolytic compositions. Additionally, given the major role of SASP in the development of Type 1 diabetes, the inhibition of SASP factors may be used to prevent Type 1 diabetes.